Company Filing History:
1 out of 1,458 
1 out of 1,091 
Years Active: 2016
Title: Dayuan Gao: Innovator in Lung Targeting Drug Delivery Systems
Introduction
Dayuan Gao is a notable inventor based in East Brunswick, NJ (US). He has made significant contributions to the field of cancer treatment through his innovative approaches to drug delivery systems. His work focuses on addressing the challenges faced by standard chemotherapy treatments, particularly for lung cancer.
Latest Patents
Gao holds a patent for a lung targeting dual drug delivery system. This invention aims to selectively deliver anti-cancer drugs to the lungs, thereby inhibiting the formation of metastases. The American Cancer Society estimated that in 2009, there would be 1,479,350 new cancer cases diagnosed in the United States, with 219,440 being lung and bronchus related. Current treatments for non-small cell lung cancer (NSCLC) include surgery, chemotherapy, radiation, laser, and photodynamic therapy, but they often yield poor results. The National Cancer Institute reports a mere 15 percent 5-year survival rate for combined cancer stages. Gao's dual drug delivery system seeks to improve these outcomes by minimizing toxicity to healthy tissues while effectively targeting cancer cells.
Career Highlights
Throughout his career, Dayuan Gao has worked at prestigious institutions such as Rutgers, the State University of New Jersey, and Princeton University. His experience in these academic environments has allowed him to develop and refine his innovative ideas in drug delivery systems.
Collaborations
Gao has collaborated with esteemed colleagues, including Robert K. Prud'homme and Patrick J. Sinko. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Dayuan Gao's work in lung targeting drug delivery systems represents a significant advancement in cancer treatment. His innovative approach addresses critical challenges in chemotherapy, offering hope for improved patient outcomes. His contributions to the field continue to inspire further research and development in cancer therapies.